Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageDebt RatioDebt to EquityEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginGross MarginInterest Coverage RatioInventory AverageInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Invested CapitalReturn on SalesTimes Interest Earned

ImmunityBio (IBRX) Times Interest Earned (2016 - 2025)

Historic Times Interest Earned for ImmunityBio (IBRX) over the last 9 years, with Q3 2025 value amounting to -$3.65.

  • ImmunityBio's Times Interest Earned fell 3322.96% to -$3.65 in Q3 2025 from the same period last year, while for Sep 2025 it was -$3.61, marking a year-over-year decrease of 2084.38%. This contributed to the annual value of -$3.0 for FY2024, which is 683.1% down from last year.
  • Latest data reveals that ImmunityBio reported Times Interest Earned of -$3.65 as of Q3 2025, which was down 3322.96% from -$4.61 recorded in Q2 2025.
  • ImmunityBio's Times Interest Earned's 5-year high stood at -$2.29 during Q3 2023, with a 5-year trough of -$27.23 in Q1 2021.
  • For the 5-year period, ImmunityBio's Times Interest Earned averaged around -$8.13, with its median value being -$3.74 (2023).
  • Its Times Interest Earned has fluctuated over the past 5 years, first plummeted by 6211.72% in 2021, then skyrocketed by 8316.42% in 2022.
  • Quarter analysis of 5 years shows ImmunityBio's Times Interest Earned stood at -$17.66 in 2021, then soared by 83.16% to -$2.97 in 2022, then grew by 9.84% to -$2.68 in 2023, then rose by 0.79% to -$2.66 in 2024, then plummeted by 37.15% to -$3.65 in 2025.
  • Its Times Interest Earned stands at -$3.65 for Q3 2025, versus -$4.61 for Q2 2025 and -$4.21 for Q1 2025.